NPPA greenlights 50% price hike for critical cancer drugs to avert supply crisis

The regulator has invoked extraordinary powers to address acute shortages of life-saving chemotherapy injections and childhood vaccines amid rising input costs.

Patients and oncologists across India have been sounding the alarm for weeks: shelves were running dry of Carboplatin and Cisplatin, two of the most essential weapons in the country’s cancer treatment arsenal. This week, the National Pharmaceutical Pricing Authority (NPPA) finally intervened. At its 147th meeting, the authority moved to break the deadlock by granting a 50% increase in the ceiling prices for these critical injections.

The move comes as a direct response to a mounting supply-side crunch. Manufacturers have long complained that the production of these formulations had become commercially unviable due to the volatile and surging costs of active pharmaceutical ingredients (APIs). By invoking its extraordinary powers under Para 19 of the Drug Price Control Order (DPCO), 2013, the NPPA has signaled that ensuring the physical availability of a drug now takes precedence over strictly maintaining older, lower price caps.

Beyond cancer: A broader supply check

The intervention isn't limited to oncology. Recognising the fragility of the supply chain for public health essentials, the regulator also sanctioned price revisions for anti-tetanus immunoglobulin and three key childhood vaccines. The NPPA’s decision followed extensive consultations with industry players, where the authority confirmed that concerns regarding shortages were not just anecdotal but reflected real systemic pressure on manufacturers.

While affordability remains a core pillar of the NPPA’s mandate, the regulator’s latest stance acknowledges a hard reality: a low price is meaningless if the medicine is not available on the pharmacy shelf. By allowing this price adjustment, the authority aims to incentivise production and stabilise the market for these life-saving medicines before the shortages lead to a full-blown public health crisis.

Why it matters

This decision marks a significant shift in how the government balances the "affordability vs. availability" equation. For years, the DPCO has been the primary tool to keep costs low for the average Indian patient. However, the current situation highlights the vulnerability of the pharmaceutical sector to global API price fluctuations.

If manufacturers cannot recover their costs, production lines slow down or stop entirely, leaving patients in the lurch. This move suggests that the NPPA is willing to adopt a more pragmatic approach to prevent the "commercial unviability" of essential drugs. Moving forward, the challenge for the authority will be ensuring that these price hikes actually translate into a swift resumption of supplies at hospitals and clinics, preventing future gaps in critical treatment protocols.